JP2025513920A - 炎症性疾患の処置 - Google Patents

炎症性疾患の処置 Download PDF

Info

Publication number
JP2025513920A
JP2025513920A JP2024561984A JP2024561984A JP2025513920A JP 2025513920 A JP2025513920 A JP 2025513920A JP 2024561984 A JP2024561984 A JP 2024561984A JP 2024561984 A JP2024561984 A JP 2024561984A JP 2025513920 A JP2025513920 A JP 2025513920A
Authority
JP
Japan
Prior art keywords
virus
protein
galectin
disease
vlp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024561984A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025513920A5 (https=
Inventor
隆司 上野
渉 赤畑
和也 後藤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CYN-K BIO, INC.
Kyoto University NUC
Original Assignee
CYN-K BIO, INC.
Kyoto University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CYN-K BIO, INC., Kyoto University NUC filed Critical CYN-K BIO, INC.
Publication of JP2025513920A publication Critical patent/JP2025513920A/ja
Publication of JP2025513920A5 publication Critical patent/JP2025513920A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2024561984A 2022-04-18 2023-04-14 炎症性疾患の処置 Pending JP2025513920A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263332037P 2022-04-18 2022-04-18
US63/332,037 2022-04-18
PCT/JP2023/015132 WO2023204148A1 (en) 2022-04-18 2023-04-14 Treatment of inflammatory conditions

Publications (2)

Publication Number Publication Date
JP2025513920A true JP2025513920A (ja) 2025-04-30
JP2025513920A5 JP2025513920A5 (https=) 2026-03-26

Family

ID=88308716

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024561984A Pending JP2025513920A (ja) 2022-04-18 2023-04-14 炎症性疾患の処置

Country Status (5)

Country Link
US (1) US20230330209A1 (https=)
EP (1) EP4511479A1 (https=)
JP (1) JP2025513920A (https=)
CN (1) CN119546752A (https=)
WO (1) WO2023204148A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118812696A (zh) * 2024-08-21 2024-10-22 南通大学附属医院 Galectin-3抗原表位肽、抗原、抗体及化学发光试剂盒

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9969986B2 (en) * 2014-08-08 2018-05-15 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein E3
EP4326858A4 (en) * 2021-04-23 2025-03-12 VLP Therapeutics, Inc. GALECTIN-TARGETED IMMUNOTHERAPY

Also Published As

Publication number Publication date
US20230330209A1 (en) 2023-10-19
WO2023204148A1 (en) 2023-10-26
EP4511479A1 (en) 2025-02-26
CN119546752A (zh) 2025-02-28

Similar Documents

Publication Publication Date Title
US12168675B2 (en) Virus-like particles and methods of use
Mezhenskaya et al. M2e-based universal influenza vaccines: a historical overview and new approaches to development
JP7701080B2 (ja) アルファウイルスレプリコン粒子
CN103282023B (zh) 狂犬病糖蛋白病毒样颗粒(vlp)
BR112015030229B1 (pt) Partícula semelhante a vírus compreendendo um polipeptídeo e um antígeno da malária, vetor, composições farmacêutica e de vacina, bem como molécula de ácido nucleico isolado
KR20250099699A (ko) 절단된 호흡기 세포융합 바이러스 f 단백질 및 이의 용도
CA3075990A1 (en) Vaccines and methods of making and using vaccines for prevention of respiratory syncytial virus (rsv) infections
US20130052226A1 (en) Compositions and methods for preventing or treating a human parvovirus infection
US20220347261A1 (en) Galectin-targeting immunotherapy
WO2023204148A1 (en) Treatment of inflammatory conditions
CA2691091A1 (en) Fusion protein, macromolecule assembled from the fusion protein, and its use in the prevention or treatment of human papillomavirus related diseases
JP6675185B2 (ja) 免疫誘導剤およびその製造方法
ES2282156T3 (es) Vacuna de acido nucleico.
WO2025084276A1 (ja) 肥満の処置
OA20123A (en) Alphavirus replicon particle.
JPWO2005090576A1 (ja) 百日咳感染症予防用ｄｎａ構築物
BR112012032922A2 (pt) construções de proteína homodimérica

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260317

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260317